This article is more than 5 years old. Information may no longer be current.

ProQR awarded innovation credit for development of LCA10 treatment

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The Dutch government has awarded ProQR a 4.7 million euro innovation credit for the development of QR-110, the company’s Leber’s congenital amaurosis 10 treatment candidate, according to a release.

Awarded through the RVO of the Ministry of Economic Affairs, the innovation credit is awarded to companies developing promising innovations, the release said.

ProQR will use the funds to conduct a phase 2/3 study of QR-110, an RNA-based oligonucleotide designed to address the underlying cause of LCA10 in the CEP290 gene, and to obtain regulatory and ethical market approval. Repayment of the credit is triggered by market approval of the treatment.